{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T17:40:10Z","timestamp":1749145210541,"version":"3.41.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","funder":[{"name":"Richard N. and Marilyn K. Witham Professorship"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To evaluate the effectiveness and safety of intravitreal melphalan (IVM) injection therapy in vitreoretinal lymphoma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Eight eyes of five biopsy-proven vitreoretinal lymphoma patients who were treated with IVM injection as a second-line therapy after intravitreal methotrexate and rituximab injections were retrospectively evaluated between January 2011 and March 2023.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The medical records of five vitreoretinal lymphoma patients (mean age of 62 years at the diagnosis) including 4 (80%) female patients and 1 (20%) male patient were retrospectively analyzed. Three patients (60%) either had a history of central nervous lymphoma or developed it during the follow-up. Patients were previously treated with a mean of five cycles of monthly intravitreal methotrexate and rituximab injections. All eyes showed complete response by the disappearance of vitreal and\/or subretinal neoplastic cells within 6 weeks after IVM injections (range, 1\u20134 injections per eye). Of 12 IVM injections, 3 (25%) injections were associated with macular edema diagnosed on optical coherence tomography at 1-month follow-up and resolved spontaneously within 5 months. The IVM administration induced new retinal pigment epithelium changes in three eyes (37%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Intravitreal melphalan injection may be effective in the management of vitreoretinal lymphoma as a second-line local therapy. Randomized clinical trials with larger numbers of patients are needed to establish the efficacy, treatment protocol, and safety of IVM injection.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000003963","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T18:03:06Z","timestamp":1698343386000},"page":"353-359","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["INTRAVITREAL MELPHALAN INJECTION AS A SECOND-LINE LOCAL THERAPY IN VITREORETINAL LYMPHOMA"],"prefix":"10.1097","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1624-5777","authenticated-orcid":false,"given":"Buse","family":"Guneri Beser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakan","family":"Demirci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250605","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/jamaophthalmol.2013.569","article-title":"Vitreoretinal lymphoma: a 20-year review of incidence, clinical and cytologic features, treatment, and outcomes","volume":"131","author":"Levasseur","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"R2-20250605","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/09273948.2021.1878233","article-title":"Consensus recommendations for the diagnosis of vitreoretinal lymphoma","volume":"29","author":"Carbonell","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"key":"R3-20250605","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jamaophthalmol.2014.4755","article-title":"Treatment strategies in primary vitreoretinal lymphoma: a 17-center European collaborative study","volume":"133","author":"Riemens","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"R4-20250605","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40942-018-0120-4","article-title":"The diagnosis and treatment of primary vitreoretinal lymphoma: a review","volume":"4","author":"Pulido","year":"2018","journal-title":"Int J Retina Vitreous"},{"key":"R5-20250605","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/ceo.13668","article-title":"Intraocular chemotherapy for vitreoretinal lymphoma: a review","volume":"48","author":"Kvopka","year":"2020","journal-title":"Clin Exp Ophthalmol"},{"key":"R6-20250605","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jamaophthalmol.2017.1810","article-title":"Intravitreal melphalan for treatment of primary vitreoretinal lymphoma: a new indication for an old drug","volume":"135","author":"Shields","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"R7-20250605","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1097\/IAE.0000000000000903","article-title":"Intravitreous chemotherapy for active vitreous seeding from retinoblastoma: outcomes after 192 consecutive injections. The 2015 howard Naquin Lecture","volume":"36","author":"Shields","year":"2016","journal-title":"Retina"},{"key":"R8-20250605","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1159\/000509080","article-title":"Intravitreal melphalan for retinoblastoma: the impact of toxicity on recurrence and ultimate globe salvage","volume":"6","author":"Berry","year":"2020","journal-title":"Ocul Oncol Pathol"},{"key":"R9-20250605","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/ICB.0000000000000798","article-title":"Intravitreal melphalan for treatment of vitreous seeding from choroidal melanoma","volume":"15","author":"Masoomian","year":"2021","journal-title":"Retin Cases Brief Rep"},{"key":"R10-20250605","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12886-020-01512-y","article-title":"Successful treatment of ciliary body medulloepithelioma with intraocular melphalan chemotherapy: a case report","volume":"20","author":"Stathopoulos","year":"2020","journal-title":"BMC Ophthalmol"},{"key":"R11-20250605","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.oret.2019.05.021","article-title":"Tumor control and visual acuity outcomes in vitreoretinal lymphoma with and without sub-retinal pigment epithelium infiltration: analysis of 125 eyes of 70 patients at a single ocular oncology center","volume":"3","author":"Dalvin","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"R12-20250605","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41433-019-0539-3","article-title":"An audit of retinal lymphoma treatment at the University of California San Francisco","volume":"34","author":"Damato","year":"2020","journal-title":"Eye (Lond)"},{"key":"R13-20250605","doi-asserted-by":"crossref","first-page":"101053","DOI":"10.1016\/j.preteyeres.2022.101053","article-title":"Challenges in the diagnosis and management of vitreoretinal lymphoma: clinical and basic approaches","volume":"90","author":"Takase","year":"2022","journal-title":"Prog Retin Eye Res"},{"key":"R14-20250605","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/bjh.17451","article-title":"Efficacy and safety of intravitreal methotrexate for vitreo-retinal lymphoma: 20 years of experience","volume":"194","author":"Habot-Wilner","year":"2021","journal-title":"Br J Haematol"},{"key":"R15-20250605","doi-asserted-by":"crossref","first-page":"1","DOI":"10.33594\/000000367","article-title":"Primary vitreoretinal lymphoma therapy monitoring: significant vitreous haze reduction after intravitreal rituximab","volume":"29","author":"Kakkassery","year":"2021","journal-title":"Neurosignals"},{"key":"R16-20250605","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1007\/s10792-021-01805-1","article-title":"Intravitreal rituximab monotherapy for management of eyes with vitreoretinal lymphoma: initial experience from India","volume":"41","author":"Rishi","year":"2021","journal-title":"Int Ophthalmol"},{"key":"R17-20250605","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000448718","article-title":"Acute hemorrhagic retinopathy following intravitreal melphalan injection for retinoblastoma: a report of two cases and technical modifications to enhance the prevention of retinal toxicity","volume":"3","author":"Aziz","year":"2017","journal-title":"Ocul Oncol Pathol"},{"key":"R18-20250605","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.ophtha.2014.03.028","article-title":"Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a preclinical and clinical study","volume":"121","author":"Francis","year":"2014","journal-title":"Ophthalmology"},{"key":"R19-20250605","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ophtha.2016.12.015","article-title":"Efficacy and toxicity of intravitreous chemotherapy for retinoblastoma: four-year experience","volume":"124","author":"Francis","year":"2017","journal-title":"Ophthalmology"},{"key":"R20-20250605","doi-asserted-by":"crossref","DOI":"10.5935\/0004-2749.2021-0037","article-title":"ERG and OCT abnormalities in retinoblastoma after melphalan intravitreous injection","author":"Albuquerque","year":"2022","journal-title":"Arq Bras Oftalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003963","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T17:03:50Z","timestamp":1749143030000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003963"}},"subtitle":["Case Series"],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000003963","relation":{},"ISSN":["0275-004X"],"issn-type":[{"type":"print","value":"0275-004X"}],"subject":[],"published":{"date-parts":[[2024,2]]}}}